131 related articles for article (PubMed ID: 18575867)
1. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
Stordal B; Davey R
Cancer Chemother Pharmacol; 2009 Mar; 63(4):661-72. PubMed ID: 18575867
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
3. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ
Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455
[TBL] [Abstract][Full Text] [Related]
5. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
Stordal B; Peters G; Davey R
Genes Chromosomes Cancer; 2006 Dec; 45(12):1094-105. PubMed ID: 16967470
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
[TBL] [Abstract][Full Text] [Related]
8. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
9. Understanding cisplatin resistance using cellular models.
Stordal B; Davey M
IUBMB Life; 2007 Nov; 59(11):696-9. PubMed ID: 17885832
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
11. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
14. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
15. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
16. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
18. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
19. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
[TBL] [Abstract][Full Text] [Related]
20. Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
Tseng SC; Huang YC; Chen HJ; Chiu HC; Huang YJ; Wo TY; Weng SH; Lin YW
Biochem Pharmacol; 2013 Feb; 85(4):583-94. PubMed ID: 23228696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
